Rheumatoid Arthritis: Newer Treatment Modalities
With the introduction of the newer nonsteroidal anti-inflammatory drugs (NSAIDs) and penicillamine, our therapeutic armamentarium for the rheumatoid disease group had been significantly broadened. ln addition, there has been a renewed interest in anti-malarials, the use of some immunosuppressive agents, and plasmapheresis. The purpose of this article is to offer a helpful therapeutic scheme in the selection of these newer anti-rheumatoid agents.
Furthermore, we have attempted to incorporate the clinical and laboratory profiles of rheumatoid patients into the treatment scheme. Rheumatoid arthritis can be divided into three subgroups: seronegative rheumatoid arthritis, sero-positive rheumatoid arthritis, and hybrid rheumatoid arthritis. Such classification offers a guideline in selecting the most suitable anti-arthritic agents.
This paper was presented at the 16 annual oonvention of the Islamic Medical Association of North America, September 2-5, 1983.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).